Table 2.

Risk perceptions

Survey QuestionResponse, n (%)
What do you tell HCV− potential recipients about the risk of HCV transmission from nonviremic (Ab+/NAT−) donors? (item denominator=107a)
 <5%68 (64)
 5%–25%16 (15)
 26%–50%3 (3)
 >50%10 (9)
 Do not discuss10 (9)
What do you tell HCV− potential recipients about the risk of chronic HCV infection after KTx from donors who are HCV Ab+/NAT+ (viremic) without DAA treatment? (item denominator=107a)
 <10%14 (13)
 10%–25%2 (2)
 26%–50%4 (4)
 51%–75%6 (6)
 76%–85%2 (2)
 86%–100%53 (50)
 We do not discuss this possible risk26 (24)
In your view, what is the risk of chronic HCV infection due to treatment failure after KTx from donors who are HCV Ab+/NAT+ and appropriate DAA therapy? (item denominator=109a)
 <1%51 (47)
 1%–5%52 (48)
 6%–10%2 (2)
 >10%4 (4)
How much reduction in waiting time (months) do you think justifies accepting a KTx from a donor who is HCV Ab+/NAT+ (viremic) for a recipient who is HCV–, versus waiting for another deceased donor organ? Mean (range) (item denominator=108a)18 (0–60)
  • HCV, hepatitis C virus; Ab, antibody; NAT, nucleic acid testing; KTx, kidney transplant; DAA, direct-acting antiviral agent.

  • a Indicates the item denominator, based on number of respondents, and accounting for contingent responses.